Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not really.
Just trying to understand your position and math? If they raised $$ below $15 then how many shares were issued? What substantial amount of royalties have been paid?
huh?
what part of my post that you are responding to in which I specifically stated that BICX raised $6 million was wrong, as you claim?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152886298
WRONG! BICX raised $6M.
Thanks for the heads- up here...GL
Scam company BICX continues with its FALSE AND MISLEADING statements. This time on the $15.00/share pricing of the $6.0 million private placement. The price was significantly below $15.00/share since a substantial Royalty Agreement also came with the common shares for the $6.0 million
not surprised though
and why is this not surprising?
because this is what scam companies do!
WRONG!! Do these people specialize in addiction or addiction treatment? More importantly do they understand that a doctor can prescribe what they feel is best for their patients?? I think NOT.
News - BioCorRx Provides 2019 Year-End Business Update
Press Release | 12/19/2019
ANAHEIM, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2019 and reported on recent corporate developments.
Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, “2019 was a transformative year for our Company as we achieved a number of major milestones. In the beginning of the year, we were awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for the development of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. This grant is expected to substantially cover our financial costs towards FDA approval and further validates the clinical potential of BICX102 for the treatment of opioid and alcohol use disorders.
“We continue to advance BICX102 through the regulatory pathway. Over the summer, we entered into a Master Services Agreement with Charles River Laboratories, Inc., to begin conducting preclinical studies of BICX102, which are still underway. We have also partnered with IRISYS to manufacture and develop BICX102. IRISYS brings extensive and valuable experience beyond manufacturing that should also contribute to our success as we move forward through the clinical and regulatory process for BICX102. Our goal for 2020 is to get IND approval so that we can start conducting human studies.
“We recently provided an update on VDM-001, a new opioid antagonist being developed to reverse opioid overdose through our partnership with VDM Biochemicals, Inc. (VDM). VDM-001 may represent an effective alternative to naloxone in the overdose reversal market. Early preclinical data showed that the effects of fentanyl, which is responsible for thousands of deaths annually, may be prevented by VDM-001. One potential benefit of VDM-001 may be a shorter and less costly manufacturing cycle as it is purely synthetic. We look forward to working with VDM in order to further explore this molecule.
“This year we launched our UnCraveRx™ program, which is a medically assisted weight loss management program that includes on-demand, virtual lifestyle support, fitness and nutrition via mobile app designed to be used in conjunction with anti-craving medication if determined medically appropriate by a patient’s treating physician and under their medical supervision. The program is designed to help providers’ client success by helping them stay on track with their weight loss goals. As we work towards expanding our provider network, we believe that the program will be a key growth revenue driver for BioCorRx.”
Lourdes Felix, CFO, COO and Director, stated, “In order to prepare us for the planned up-listing to the Nasdaq Capital Markets, we recently converted the note with Alpine Creek Partners, which eliminates $4.16 million of liabilities from our balance sheet. This significantly enhances our capital structure and dramatically improves our balance sheet. Notably, in the second quarter of this year, we raised $6 million in a private placement at $15 per share, which was significantly above market. We continue to receive strong support from our current investors as well as Alpine Creek, a strategic partner since 2016. For this reason, we decided to withdraw the S-1 registration statement. Our goal is to minimize dilution as we advance BICX102 through the regulatory pathway and we believe withdrawing the S-1 registration statement is in the best interest of our shareholders. We would like to wish everyone happy and healthy holidays and we look forward to providing further updates in the new year.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit www.beataddiction.com for more information on the BioCorRx Recovery Program. The UnCraveRx™ Weight Loss Program is also a medication assisted program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
they should get a job and stop complaining about everything that is good
Thank you for the update...let us know when something actually happens.
"Consumer advocacy group Public Citizen last week urged the Food and Drug Administration to investigate BioCorRx and Louisiana's Department of Public Safety and Corrections.
Although Naltrexone is FDA-approved and has existed for decades in both pill and injectable form, the implant version has not been cleared for use on humans, Public Citizen said in a Nov. 20 letter. The group also said BioCorRx should have conducted the clinical trial in coordination with a FDA review board."
WRONG!!!!!!!! the prisoner said it worked and thanks his life to it.
WRONG!
In order for the implant to be used in the first place it had to be signed off by a Judge, a Physician and the patent.
Second the implant has been legally used for over 4 years under the Federal Drug Compounding and off label laws.
While the company can not sell an implant because the delivery system is is not FDA approved for sale a Physician can have a compounding Pharmacy make one from the approve drug naltrexone and the Physician can implant it legally.
Compounding Laws and Policies
TIMBER! - BICX IN BIG TIME TROUBLE!
https://www.cbsnews.com/news/opioid-addiction-treatment-former-addict-says-implant-changed-his-life-critics-call-him-a-guinea-pig/?intcid=CNI-00-10aaa3a
"Although Dutruch said the treatment has helped him turn his life around, some critics say he has been used. Consumer advocacy group Public Citizen last week urged the Food and Drug Administration to investigate BioCorRx and Louisiana's Department of Public Safety and Corrections.
Although Naltrexone is FDA-approved and has existed for decades in both pill and injectable form, the implant version has not been cleared for use on humans, Public Citizen said in a Nov. 20 letter. The group also said BioCorRx should have conducted the clinical trial in coordination with a FDA review board.
"The failure to comply with the requirements for the protection of human subjects represents a serious violation of the basic ethical principles of respect for persons, beneficence and justice," Dr. Michael Carome, Public Citizen's health research director, said in a statement. "A drug company should not be allowed to go into a prison and start treating the inmates like unwitting guinea pigs."
Public Citizen said it obtained emails between BioCorRx and Louisiana corrections officials that show the company didn't seek FDA approval to test the implant."
when speaking to their investor relations they also said that they still plan on up listing and it has nothing to do with withdrawing their s1. they said everything is still on track. so maybe a good time to buy more now that it fell under 4 dollars again...
I spoke to their pr company and they said that they withdrew the s1 because they did not need to raise anymore money because they got that 6 mill from one of their board members
It seems like when the grant money is gone so is bicx. They seem to be making no progress on any of their priorities.
It seems like when the grant money is gone so is bicx. They seem to be making no progress on any of their priorities.
Maybe they are going back to Penny stock land and reverse the reverse split
Why are they not uplisting
Why are they not uplisting
Is there anyway positive to look at this news?
More troulbe! - BICX files Withdrawal of Registration Statement with SEC
https://www.sec.gov/Archives/edgar/data/1443863/000147793219007007/bicx_rw.htm
Look for an FDA letter to BICX warning them from using implants not approved by the FDA
then look for a second letter from the FDA demanding that BICX stop with the implant program until it is approved by the FDA
then look for the SEC Division of Enforcement getting involved with BICX and a potential suspension of the stock
This prisoner knew what they were signing up for.. I am sure that they signed something acknowledging that.. Brady is not stupid!!
They were aware it was not FDA approved... the best thing is that it worked!! this prisoner admits it worked!!! I hope he takes it to court and this news goes viral... All the great publicity because that's the best free publicity they can get!!! it worked!!! this prisoner is trying to capitalize on suing a company that helped him!! a very opportunistic move in the worst way!! go bicx! Hope everyone will be aware of this!! approve it FDA!! look at it.. it works!!!
First: the implant can't be a scam if it works...
Second: the implant was donated not "sold"
Third: You're allowed to use something not approved by the FDA if that's disclosed, which in this case it was. The individual himself said he was aware of that fact.
Thank you...pleasure doing business.
Huh?
what court?
Let just see what scam company BICX does after the FDA prohibits BICX from selling and using these implants in the market until it is fully tested in humans
then there is the criminal liability for already using drugs not approved by the FDA
IT WORKED!!! THAT IS THE TAKE-AWAY FROM THIS!! IT WORKED!!! GO BICX!!
That's not going anywhere in court.
"Consumer advocacy group Public Citizen last week urged the Food and Drug Administration to investigate BioCorRx and Louisiana's Department of Public Safety and Corrections.
Although Naltrexone is FDA-approved and has existed for decades in both pill and injectable form, the implant version has not been cleared for use on humans, Public Citizen said in a Nov. 20 letter. The group also said BioCorRx should have conducted the clinical trial in coordination with a FDA review board."
TIMBER! - BICX IN BIG TIME TROUBLE!
https://www.cbsnews.com/news/opioid-addiction-treatment-former-addict-says-implant-changed-his-life-critics-call-him-a-guinea-pig/?intcid=CNI-00-10aaa3a
"Although Dutruch said the treatment has helped him turn his life around, some critics say he has been used. Consumer advocacy group Public Citizen last week urged the Food and Drug Administration to investigate BioCorRx and Louisiana's Department of Public Safety and Corrections.
Although Naltrexone is FDA-approved and has existed for decades in both pill and injectable form, the implant version has not been cleared for use on humans, Public Citizen said in a Nov. 20 letter. The group also said BioCorRx should have conducted the clinical trial in coordination with a FDA review board.
"The failure to comply with the requirements for the protection of human subjects represents a serious violation of the basic ethical principles of respect for persons, beneficence and justice," Dr. Michael Carome, Public Citizen's health research director, said in a statement. "A drug company should not be allowed to go into a prison and start treating the inmates like unwitting guinea pigs."
Public Citizen said it obtained emails between BioCorRx and Louisiana corrections officials that show the company didn't seek FDA approval to test the implant."
FINALLY A NEW BRADY INTERVIEW LINK https://www.proactiveinvestors.com/companies/news/908472/biocorrx-presents-new-preclinical-data-showing-vdm-001-blocks-fentanyl-908472.html
https://www.cbsnews.com/news/opioid-addiction-treatment-former-addict-says-implant-changed-his-life-critics-call-him-a-guinea-pig/?intcid=CNI-00-10aaa3a
LOLOL...some guy really trying to sue BICX for helping folks get freedom from addiction. Unbelievable. Good luck with whatever BS argument he has and what a waste of time.
Any publicity is good publicity I guess.
Found this in YAHOO! FINANCE
https://finance.yahoo.com/news/biocorrx-subsidiary-biocorrx-pharmaceuticals-provides-133010055.html
that is great news. wonder why brady hasn't ever mentioned this. why has he been so quiet. they have to be working on something! GO BICX
I think it’s obvious at this point what he meant ! ??
Can you expand on your evaluation “Timber”?
TIMBER! BICX files 10Q
https://www.sec.gov/Archives/edgar/data/1443863/000147793219006570/bicx_10q.htm
Remember we don't have a whole lot of shares outstanding. Won't take much to move.
It only took 12K shares to move bicx over 50%. There is also a bid for 4125 x $4 - someone must know something. Maybe they got some whales at the conferences the last 2 weeks.
Somethings up
Up 50% trading at $4. Hmmm
Whoaaa! $2.46 - New 52 week Low!
how long before the stock price drops to below $2.00?
below $1.00?
Are you saying BICX didn’t raise $6,000,000?
actually, the big question would be as to when the SEC Division of Enforcement would begin initial fraud inquiries on the the BICX fraudulent $15.00/share private placement statements in its press releases
has BICX already received a Wells Notice from the SEC?
Followers
|
132
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12606
|
Created
|
10/10/10
|
Type
|
Free
|
Moderators |
About BioCorRxProgram OverviewBioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States. The program consists of two components:BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results. BioCorRx’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose. |
TechnologyNaltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence. Learn more about the side effects of naltrexone. Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety. While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment. While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism. The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol. |
Mission, Vision, ValuesMissionBioCorRx is focused on providing leadership and innovation for the treatment of alcoholism by offering a high-quality, comprehensive and cost-effective recovery program that allows patients and their loved ones to celebrate freedom from the cycle of alcohol addiction. Our program is built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering alcoholics. VisionBioCorRx strives to be the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. By providing patients a "Fresh Start" on life, they have the opportunity to live happier, healthier, more productive lives away from the damaging impact of alcohol. We have built an organization that is committed to nurturing research for cutting-edge alcohol recovery technologies and integrating those technologies with comprehensive alcohol recovery treatment programs. ValuesBioCorRx provides the opportunity and tools to treatment centers so they can help patients live happier, healthier, and more productive lives to those suffering from alcohol addiction (as well as their family and friends) by helping them break the addiction cycle and live alcohol-free. We want patients to celebrate freedom from the past and hope for the future. Our team consists of physicians, coaches, founders and management that are committed to providing high-quality services and adherence to ethical care. Our goal is to give our treatment center partners the ability to deliver our program in a timely, warm and compassionate way to give patients, as well as their families and friends, peace of mind. To achieve this, BioCorRx has built its program around highly-qualified alcohol addiction specialists and effective treatment solutions. We are committed to quality and continuous improvement in order to meet our partners’ needs for an individualized program dedicated to alcohol addiction recovery. |
Investors OverviewBioCorRx is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US. More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over $220 billion a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer ($196 billion) and obesity ($133 billion). BioCorRx intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees. Business ModelBioCorRx’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally. BioCorRx's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate. Stock Price & ChartsBioCorRx is a fully reporting company. Financial reports and other reports are available for view or by visiting the OTCBB.com online website. Audited financial reports are available quarterly. Company Structure Details
|
BICX Chart
Key Executives
• Kent Emry - CEO, Director
• Brady Granier -COO, Director
• Lourdes Felix -CFO, Director
• Dr. Jorge Andrade, Jr. - Director
• Neil Muller -Co-Founder and President, Director
Locations
Locations of independently owned clinics using our Fresh Start Program
Start Fresh Recovery
720 N. Tustin Ave.
Suite 206
Santa Ana, CA 92705
714-541-6100
800-916-1099
www.startfreshrecovery.com
www.stopdrinkingUSA.com
Start Fresh Executive Recovery
367 E Virginia Ave
Phoenix, AZ 85004
855-393-HOPE (4673)
www.ExecutiveRecovery.net
Fresh Start Private Florida
1415 Panther Lane
Suites 313-320
Naples, FL 34109
800-985-7574
www.FreshStartPrivateFlorida.com
Start Fresh Alcohol Recovery Center
2827 S. 88th St
Omaha NE 68124
402-884-1221
www.startfreshNE.com
Coming Soon!
Insider Interview Links
December 2, 2013 - thewallstreetanalyzer.com Interview with Brady Granier COO
November 14, 2013 - SmallCapVoice Interview with Kent Emry CEO
October 2, 2013 - SmallCapVoice Interview with Brady Granier COO
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |